-
1
-
-
77953780456
-
Applications of a national HIV drug resistance database: Surveillance and development of genotypic resistance algorithms
-
abstr. 16
-
Anta, L., J. L. Blanco, M. J. Pérez-Elías, F. García, M. Leal, E. Ribera, J. A. Iribarren, F. Gutiérrez, I. Viciana, A. Aguilera, J. Pedreira, J. L. Gómez-Sirvent, V. Soriano, and C. de Mendoza. 2009. Applications of a national HIV drug resistance database: surveillance and development of genotypic resistance algorithms, abstr. 16. 7th European HIV Drug Resistance Workshop, Stockholm, Sweden.
-
(2009)
7th European HIV Drug Resistance Workshop, Stockholm, Sweden
-
-
Anta, L.1
Blanco, J.L.2
Pérez-Elías, M.J.3
García, F.4
Leal, M.5
Ribera, E.6
Iribarren, J.A.7
Gutiérrez, F.8
Viciana, I.9
Aguilera, A.10
Pedreira, J.11
Gómez-Sirvent, J.L.12
Soriano, V.13
De Mendoza, C.14
-
2
-
-
33750338185
-
Genotypic changes in HIV-1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir
-
Baxter, J., J. Schapiro, C. Boucher, V. Kohlbrenner, D. Hall, J. Scherer, and D. L. Mayers. 2006. Genotypic changes in HIV-1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J. Virol. 80:10794-10801.
-
(2006)
J. Virol.
, vol.80
, pp. 10794-10801
-
-
Baxter, J.1
Schapiro, J.2
Boucher, C.3
Kohlbrenner, V.4
Hall, D.5
Scherer, J.6
Mayers, D.L.7
-
3
-
-
34047207229
-
Efficacy and safety of darunavirritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials
-
the POWER 1 and 2 Study Groups
-
Clotet, B., N. Bellos, J. M. Molina, D. Cooper, J. Goffard, A. Lazzarin, A. Wöhrmann, C. Katlama, T. Wilkin, R. Haubrich, C. Cohen, C. Farthing, D. Jayaweera, M. Markowitz, P. Ruane, S. Spinosa-Guzman, E. Lefebvre, and the POWER 1 and 2 Study Groups. 2007. Efficacy and safety of darunavirritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 369:1169-1178.
-
(2007)
Lancet
, vol.369
, pp. 1169-1178
-
-
Clotet, B.1
Bellos, N.2
Molina, J.M.3
Cooper, D.4
Goffard, J.5
Lazzarin, A.6
Wöhrmann, A.7
Katlama, C.8
Wilkin, T.9
Haubrich, R.10
Cohen, C.11
Farthing, C.12
Jayaweera, D.13
Markowitz, M.14
Ruane, P.15
Spinosa-Guzman, S.16
Lefebvre, E.17
-
4
-
-
66349091714
-
Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen
-
Delaugerre, C., J. Pavie, P. Palmer, J. Ghosn, S. Blanche, L. Roudiere, S. Dominguez, E. Mortier, J. M. Molina, and P. de Truchis. 2008. Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen. AIDS 22:1809-1813.
-
(2008)
AIDS
, vol.22
, pp. 1809-1813
-
-
Delaugerre, C.1
Pavie, J.2
Palmer, P.3
Ghosn, J.4
Blanche, S.5
Roudiere, L.6
Dominguez, S.7
Mortier, E.8
Molina, J.M.9
De Truchis, P.10
-
5
-
-
34247863946
-
Tipranavir: A new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients
-
de Mendoza, C., J. Morelló, P. Garcia-Gascó, S. Rodríguez-Novoa, and V. Soriano. 2007. Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients. Expert Opin. Pharmacother. 8:839-850.
-
(2007)
Expert Opin. Pharmacother.
, vol.8
, pp. 839-850
-
-
De Mendoza, C.1
Morelló, J.2
Garcia-Gascó, P.3
Rodríguez-Novoa, S.4
Soriano, V.5
-
6
-
-
48449099374
-
Identification of mutations predictive of a diminished response to darunavir/ritonavir: Analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and 2
-
abstr. 54
-
De Meyer, S., I. Dierynck, E. Lathouwers, B. Van Baelen, T. Vangeneugden, T. S. Spinosa-Guzman, G. Picchio, and M. P. de Béthune. 2008. Identification of mutations predictive of a diminished response to darunavir/ritonavir: analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and 2, abstr. 54. 6th European Resistance Workshop, Budapest, Hungary.
-
(2008)
6th European Resistance Workshop, Budapest, Hungary
-
-
De Meyer, S.1
Dierynck, I.2
Lathouwers, E.3
Van Baelen, B.4
Vangeneugden, T.5
Spinosa-Guzman, T.S.6
Picchio, G.7
De Béthune, M.P.8
-
7
-
-
33746576313
-
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1 infected patients at 48 weeks in the randomized evaluation of strategic intervention in multidrug resistant patients with tipranavir (RESIST studies): An analysis of combined data from two randomised open-label trials
-
the RESIST Investigator Group
-
Hicks, C., P. Cahn, D. Cooper, S. Walmsleg, C. Katlama, B. Clotet, A. Lazzarin, M. A. Johnson, D. Neubacher, D. Mayers, H. Valdez, and the RESIST Investigator Group. 2006. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1 infected patients at 48 weeks in the randomized evaluation of strategic intervention in multidrug resistant patients with tipranavir (RESIST studies): an analysis of combined data from two randomised open-label trials. Lancet 368:466-475.
-
(2006)
Lancet
, vol.368
, pp. 466-475
-
-
Hicks, C.1
Cahn, P.2
Cooper, D.3
Walmsleg, S.4
Katlama, C.5
Clotet, B.6
Lazzarin, A.7
Johnson, M.A.8
Neubacher, D.9
Mayers, D.10
Valdez, H.11
-
8
-
-
77949324191
-
Update of the drug resistance mutations in HIV-1: December 2009
-
Johnson, V., F. Brun-Vézinet, B. Clotet, H. Günthard, D. Kuritzkes, D. Pillay, J. M. Schapiro, and D. Richman. 2009. Update of the drug resistance mutations in HIV-1: December 2009. Top. HIV Med. 17:138-145.
-
(2009)
Top. HIV Med.
, vol.17
, pp. 138-145
-
-
Johnson, V.1
Brun-Vézinet, F.2
Clotet, B.3
Günthard, H.4
Kuritzkes, D.5
Pillay, D.6
Schapiro, J.M.7
Richman, D.8
-
9
-
-
55049134097
-
Resilience to resistance of HIV-1 protease inhibitors: Profile of darunavir
-
Lefebvre, E., and C. Schiffer. 2008. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev. 10:131-142.
-
(2008)
AIDS Rev.
, vol.10
, pp. 131-142
-
-
Lefebvre, E.1
Schiffer, C.2
-
10
-
-
33747122063
-
Protease mutations associated with higher or lower than expected tipranavir susceptibility based on the TPV mutation score
-
abstr. 637
-
Parkin, N., and C. Chappey. 2006. Protease mutations associated with higher or lower than expected tipranavir susceptibility based on the TPV mutation score, abstr. 637. 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO.
-
(2006)
13th Conference on Retroviruses and Opportunistic Infections, Denver, CO
-
-
Parkin, N.1
Chappey, C.2
-
11
-
-
34548749164
-
Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors
-
Poveda, E., C. de Mendoza, L. Martin-Carbonero, A. Corral, V. Briz, J. González-Lahoz, and V. Soriano. 2007. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J. Antimicrob. Chemother. 60:885-888.
-
(2007)
J. Antimicrob. Chemother.
, vol.60
, pp. 885-888
-
-
Poveda, E.1
De Mendoza, C.2
Martin-Carbonero, L.3
Corral, A.4
Briz, V.5
González-Lahoz, J.6
Soriano, V.7
-
12
-
-
70249098632
-
Improving the prediction of virologic response to tipranavir: The development of a tipranavir weighted score
-
abstr. 94
-
Scherer, J., C. Boucher, J. Baxter, J. Schapiro, W. Kohlbrenner, and D. Hall. 2008. Improving the prediction of virologic response to tipranavir: the development of a tipranavir weighted score, abstr. 94. 6th European Resistance Workshop, Budapest, Hungary.
-
(2008)
6th European Resistance Workshop, Budapest, Hungary
-
-
Scherer, J.1
Boucher, C.2
Baxter, J.3
Schapiro, J.4
Kohlbrenner, W.5
Hall, D.6
-
13
-
-
67649533587
-
Improved tipranavir weighted score validated in Italian treatment-experienced patient cohort
-
abstr. 98
-
Scherer, J., F. Maggiolo, C. Perno, H. Gellermann, A. Di Biagio, S. LoCaputo, A. Cattelan, C. Mussini, M. Santoro, and D. Hall. 2009. Improved tipranavir weighted score validated in Italian treatment-experienced patient cohort, abstr. 98. 7th European Resistance Workshop, Stockholm, Sweden.
-
(2009)
7th European Resistance Workshop, Stockholm, Sweden
-
-
Scherer, J.1
Maggiolo, F.2
Perno, C.3
Gellermann, H.4
Di Biagio, A.5
LoCaputo, S.6
Cattelan, A.7
Mussini, C.8
Santoro, M.9
Hall, D.10
-
14
-
-
67649533587
-
Improved tipranavir weighted score predicts virologic response in diverse treatmentexperienced patient populations
-
abstr. 94
-
Scherer, J., J. Schapiro, F. Maggiolo, C. Perno, C. Boucher, J. Baxter, H. Gellermann, C. Tilke, M. M. Santoro, and D. B. Hall. 2009. Improved tipranavir weighted score predicts virologic response in diverse treatmentexperienced patient populations, abstr. 94. 7th European Resistance Workshop, Stockholm, Sweden.
-
(2009)
7th European Resistance Workshop, Stockholm, Sweden
-
-
Scherer, J.1
Schapiro, J.2
Maggiolo, F.3
Perno, C.4
Boucher, C.5
Baxter, J.6
Gellermann, H.7
Tilke, C.8
Santoro, M.M.9
Hall, D.B.10
-
15
-
-
60749098495
-
Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients
-
Spagnuolo, V., N. Gianotti, E. Seminari, L. Galli, G. Fusetti, S. Salpietro, A. Lazzarin, and A. Castagna. 2009. Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients. J. Acquir. Immune. Defic. Syndr. 50:192-195.
-
(2009)
J. Acquir. Immune. Defic. Syndr.
, vol.50
, pp. 192-195
-
-
Spagnuolo, V.1
Gianotti, N.2
Seminari, E.3
Galli, L.4
Fusetti, G.5
Salpietro, S.6
Lazzarin, A.7
Castagna, A.8
|